Single ubiquitin tags on non-histone proteins shape health and disease

A single ubiquitin molecule attached to a protein may look like a minor chemical footnote, but a new comprehensive review argues it is one of the most versatile switches in human biology. Writing in Cellular and Molecular Life Sciences, a team led by researchers at China Medical University surveys the field of non-histone protein monoubiquitination, the attachment of exactly one ubiquitin to a lysine residue on a substrate protein, and maps how this modification steers DNA repair, gene expression, signaling, membrane trafficking, autophagy and immunity. When the switch malfunctions, the review concludes, the consequences span cancer, neurodegeneration, immune disorders and metabolic disease, making the monoubiquitination machinery a rich source of therapeutic targets.

Ubiquitin is a small, highly conserved 76-amino-acid protein whose covalent attachment to other proteins was once viewed mainly as a destruction tag. The canonical ubiquitination reaction proceeds through a three-enzyme cascade: a ubiquitin-activating enzyme (E1) charges ubiquitin in an ATP-dependent thioester reaction, a ubiquitin-conjugating enzyme (E2) transfers the activated ubiquitin, and a ubiquitin ligase (E3) catalyzes formation of an isopeptide bond between the ubiquitin C-terminal glycine and a lysine side chain on the substrate. When the substrate lysine receives a single ubiquitin, the modification is called monoubiquitination; when ubiquitin chains are built on that first ubiquitin, often through its lysine 48 or lysine 63 residues, the result is polyubiquitination. The two outcomes are functionally distinct, and the review emphasizes that monoubiquitination is not simply an intermediate step but a signal in its own right.

The authors draw a sharp contrast with the better-known story of histone monoubiquitination. Histones, the proteins around which DNA is wrapped, carry monoubiquitin marks at specific residues that primarily regulate chromatin structure and transcription. Non-histone monoubiquitination, by comparison, touches a far broader range of substrates and processes. The review organizes these into six major arenas: the DNA damage response, transcriptional regulation, signal transduction, endocytic trafficking, autophagy and immunity. In each case, a single ubiquitin acts as a portable molecular address label, changing where a protein goes, what it binds, or how long it survives without necessarily committing it to degradation.

The mechanistic logic is subtle. Unlike lysine-48-linked polyubiquitin, which flags proteins to the 26S proteasome for destruction, a monoubiquitin mark typically alters protein behavior in other ways. It can create binding sites for ubiquitin-binding domains on partner proteins, mediate incorporation of proteins into membranes or vesicles, control protein complex assembly and disassembly, or adjust enzymatic activity. Specificity is achieved through a combination of E3 ligase recognition motifs, docking sequences on substrates, and spatial organization within the cell. Deubiquitylating enzymes, which cleave ubiquitin from substrates, provide the counterweight, and the balance between writing and erasing monoubiquitin marks determines the functional state of hundreds of proteins at any moment.

Among the most consequential examples is the DNA damage response. Monoubiquitination of proliferating cell nuclear antigen, the sliding clamp that tethers DNA polymerases, serves as a master switch that redirects DNA synthesis from high-fidelity replication to translesion synthesis, allowing the replication machinery to bypass lesions that would otherwise stall it. This single modification therefore influences both genome stability and mutation rate, with direct implications for cancer initiation and treatment resistance. The review also discusses monoubiquitination of repair factors and signaling proteins that coordinate the cellular decision between repair, cell-cycle arrest and programmed death after DNA injury.

In signal transduction and membrane traffic, monoubiquitination acts as a routing signal. Receptors at the cell surface are monoubiquitinated after ligand binding, which directs them into the endocytic pathway and toward degradation or recycling, thereby tuning the intensity and duration of signaling. The same principle governs the trafficking of transporters, adhesion molecules and viral proteins. In autophagy, monoubiquitin marks on selective cargo receptors and on components of the autophagy machinery help determine what the cell consumes during stress. The immune system exploits the chemistry as well, with monoubiquitination modulating receptor signaling, antigen presentation and inflammatory pathways, and pathogens in turn have evolved strategies to hijack or block these marks.

The review’s therapeutic argument rests on the observation that dysregulated monoubiquitination is implicated in a wide range of human diseases. Aberrant monoubiquitin marks on tumor suppressors, oncogenes and cell-cycle regulators contribute to uncontrolled proliferation and metastasis. Faulty monoubiquitination of neuronal proteins is linked to protein aggregation and impaired synaptic function in neurodegenerative conditions. In immune and inflammatory disorders, miswritten monoubiquitin signals disturb the thresholds that normally keep immune activation in check. Because each mark is written by a specific E3 ligase and erased by specific deubiquitylating enzymes, the pathway offers many discrete intervention points rather than a single blunt target.

That granularity is already visible in the clinic. Proteasome inhibitors such as bortezomib exploit ubiquitin-dependent degradation in multiple myeloma, and a growing pharmacopeia of E3 ligase modulators and deubiquitylating enzyme inhibitors is in development for cancer and immune disease. The review suggests that monoubiquitination-specific mechanisms, distinct from polyubiquitination and proteasomal degradation, could support next-generation drugs with greater precision and fewer side effects. It also highlights technical advances, including ubiquitin remnant mass spectrometry and ubiquitin-chain-specific enrichment methods, that are expanding the catalog of monoubiquitinated substrates and making the modification tractable for drug discovery.

The authors, led by Kedian Chen, Haoguo Wang, Siqi Zhang and Siyao Qu with corresponding authors Chengzhong Xing, Pengcheng Jiang, Lei Qiao and Jingwei Liu, frame the review as a bridge between fundamental ubiquitin biochemistry and translational medicine. They acknowledge open questions, including how monoubiquitination sites are selected among competing lysines, how writers and erasers are themselves regulated, and how monoubiquitin signals are decoded differently in different cellular contexts. Answering these questions, they argue, will be essential for converting the growing mechanistic knowledge into reliable biomarkers and therapies.

For a modification that involves adding a single 8.5-kilodalton protein to a lysine residue, monoubiquitination has turned out to carry remarkable regulatory weight. The review’s synthesis makes clear that the field has moved past the era when ubiquitin was seen only as a destruction tag, and that the single-ubiquitin signal now stands alongside phosphorylation and acetylation as a central axis of cellular control. As the catalog of monoubiquitinated non-histone proteins grows and the disease connections multiply, the authors conclude, understanding and manipulating this modification may become a defining challenge for molecular medicine in the coming decade.

Subject of Research: Non-histone protein monoubiquitination: from cellular functions to mechanism and therapeutic potential of human diseases

Article Title: Non-histone protein monoubiquitination: from cellular functions to mechanism and therapeutic potential of human diseases

Article References: Chen, K., Wang, H., Zhang, S., Qu, S., Chang, X., Li, S., Li, A., Chen, X., Wang, S., Di, X., Wang, R., Xing, C., Jiang, P., Qiao, L., & Liu, J. (2026). Non-histone protein monoubiquitination: from cellular functions to mechanism and therapeutic potential of human diseases. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06479-5

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06479-5

Keywords: monoubiquitination, non-histone proteins, ubiquitin, post-translational modification, E3 ubiquitin ligase, deubiquitylating enzymes, DNA damage response, autophagy, endocytic trafficking, cancer therapy, Non-histone, protein